What is the optimal empiric antibiotic regimen for a patient with moderate‑to‑severe burns covering ≥20 % of total body surface area who has no known drug allergies?

Best Antibiotic Therapy for Moderate-to-Severe Burns

For patients with moderate-to-severe burns (≥20% TBSA) without signs of septic shock, systemic antibiotic prophylaxis is NOT recommended—antibiotics should only be initiated when there is documented or highly suspected infection. This is a critical distinction that prevents unnecessary antibiotic exposure and resistance development 1.

Key Principle: No Prophylactic Antibiotics for Burns

The Surviving Sepsis Campaign 2016 guidelines explicitly recommend against sustained systemic antimicrobial prophylaxis in patients with severe inflammatory states of noninfectious origin, including burn injury 1. Burns create a severe inflammatory state that mimics infection, but prophylactic antibiotics do not improve outcomes and contribute to resistance patterns.

When to Initiate Antibiotics

Start empiric antibiotics only when:

• Clinical signs of infection are present (fever, hemodynamic instability, purulent drainage, cellulitis extending beyond burn margins)
• Sepsis or septic shock develops
• Documented positive cultures from blood or tissue biopsy

Empiric Antibiotic Regimen for Infected Burns

For Complicated Skin and Soft Tissue Infections (Including Infected Burns):

Primary empiric regimen should include:

1. Anti-MRSA coverage (choose one):

   • Vancomycin IV (most commonly recommended) 2, 3
   • Linezolid 600 mg IV/PO twice daily 2, 3
   • Daptomycin 4 mg/kg IV once daily 2, 3

2. Broad-spectrum Gram-negative coverage (choose one):

   • Piperacillin-tazobactam (most commonly used in burn units) 4, 5
   • Ceftazidime (particularly effective against Pseudomonas) 6
   • Imipenem or meropenem (for suspected multidrug-resistant organisms) 7

3. Consider adding aminoglycoside for severe infections:

   • Amikacin (shows excellent sensitivity against burn wound pathogens including Klebsiella, Staphylococcus, and Pseudomonas) 6
   • Netilmicin (alternative with good activity) 7, 8

If Septic Shock Develops:

Use combination therapy with at least two different antimicrobial classes 1:

• Extended-spectrum β-lactam (piperacillin-tazobactam or ceftazidime) PLUS
• Either aminoglycoside (amikacin) OR fluoroquinolone (levofloxacin)

This combination is specifically recommended for Pseudomonas aeruginosa coverage in septic shock 1.

Microbiological Considerations

Expected pathogens evolve over time:

• Early (<48-72 hours): Gram-positive cocci predominate, especially Staphylococcus aureus (including MRSA) 9
• Later hospitalization: Gram-negative bacilli become prevalent—Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii 6, 5, 9
• Fungal infections: Consider in prolonged hospitalization or immunocompromised patients 1, 5

Critical Management Principles

Obtain Cultures Before Starting Antibiotics:

• At least 2 sets of blood cultures (aerobic and anaerobic) 1, 10
• Tissue biopsy from burn wound (gold standard for infection diagnosis) 9
• Do NOT delay antibiotics >45 minutes for culture collection 1

Initiate Antibiotics Within 1 Hour:

If sepsis or septic shock is suspected, start IV antimicrobials within one hour of recognition 1, 10

De-escalation Strategy:

• Reassess daily for potential narrowing of spectrum 1
• Discontinue combination therapy within 3-5 days once clinical improvement occurs or susceptibilities are known 1
• Transition to targeted single-agent therapy based on culture results 1

Duration of Therapy:

• 7-10 days for most serious infections 1
• Longer courses may be needed for:
  • Slow clinical response
  • Staphylococcus aureus bacteremia
  • Undrainable infection foci
  • Immunocompromised patients 1

Optimize Dosing:

Burn patients have altered pharmacokinetics requiring dose optimization 1:

• Vancomycin: Loading dose 25-30 mg/kg, target trough 15-20 mg/L 1
• Aminoglycosides: Once-daily dosing (gentamicin 5-7 mg/kg equivalent) 1
• Consider therapeutic drug monitoring

Common Pitfalls to Avoid

1. Do NOT use prophylactic antibiotics in non-infected burns—this increases resistance without benefit 1

2. Do NOT confuse colonization with infection—burn wounds are commonly colonized; treat only documented infection 9

3. Do NOT continue combination therapy beyond 3-5 days without clear indication 1

4. Do NOT use standard dosing—burn patients require pharmacokinetic optimization and often higher doses 1

5. Do NOT delay surgical debridement—antibiotics are adjunctive to source control 2, 3

For Multidrug-Resistant Organisms

If MDR Pseudomonas or Acinetobacter develops:

• Colistin (polymyxin E) has re-emerged as highly effective 5
• Consider newer agents: ceftolozane-tazobactam, ceftazidime-avibactam 9
• Combination therapy may be warranted for difficult-to-treat pathogens 1